Home > Inhibitors & Agonists > Ras-Raf-MAPK-ERK > Ribosomal S6 Kinase (RSK)
Cat. No. Product name CAS No.
DC7098 BI-D1870 Featured

BI-D1870 is a small molecule, specific inhibitor of p90 RSK (ribosomal S6 kinase) isoforms RSK1, RSK2, RSK3 and RSK4, both in vitro and in vivo, with IC50s are 31 nM, 24 nM, 18 nM, 15 nM, respectively.

DC9617 CMK

CMK is a RSK2 kinase inhibitor.

DC7696 FMK Featured

Fmk is an irreversible ribosomal S6 kinase inhibitor 1/2 inhibitor.

DC8811 LJH-685 Featured

LJH685 is a selective and potent RSK inhibitor.

DC8812 LJI-308 Featured

LJI308 is a selective and potent RSK inhibitor.

DC7943 LYS6K2(LY2584702) tosylate salt Featured

LY-2584702 is an orally available inhibitor of p70S6K signaling; inhibits p70S6K and prevents phosphorylation of the S6 subunit of ribosomes.

DC10751 M2698 Featured

M2698 is a potent dual-inhibitor of p70S6K and Akt that affects tumor growth in mouse models of cancer and crosses the blood-brain barrier.

DC7599 SC1(Pluripotin) Featured

SC1(Pluripotin) is a sustainer of mES self-renewal and ERK 1 inhibitor

DC8239 SL 0101-1

SL 0101-1 is a selective inhibitor of p90 Rsk (ribosomal S6 kinase) (IC50 = 89 nM for Rsk-2).

DC41328 Eudesmin

Eudesmin ((-)-Eudesmin) impairs adipogenic differentiation via inhibition of S6K1 signaling pathway. Eudesmin possesses diverse therapeutic effects, including anti-tumor, anti-inflammatory, and anti-bacterial activities.

DC47347 RSK4-IN-1

RSK4-IN-1 is identified with potent RSK4 inhibitory activity with an IC50 value of 9.5 nM.

DC70703 PMD-026

PMD-026 (PMD026) is an oral, reversible small molecule inhibitor of ribosomal S6 kinase (RSK1-4) with IC50 of 2 nM (RSK1), 0.7 nM (RSK2), 0.9 nM (RSK3) and 2 nM (RSK4).PMD-026 decreased YB-1 phosphorylation as well as AR V7 mRNA and AR variants expressions in 22Rv1 cells.PMD-026 suppressed cell proliferation alone and in combination with the second-generation antiandrogens enzalutamide and darolutamide by inducing cellular apoptosis and G2/M arrest.PMD-026 suppressed tumor growth, and the combination of PMD-026 and enzalutamide inhibited tumor growth more prominently than single treatment in mouse xenograft models.

Page 1 / Total 1 FirstPrevNextLastGoto